Humacyte’s tissue-engineered blood vessel for vascular trauma gets nod
Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s.
HQ Team February 16, 2024: The U.S. Food and Drug Administration (FDA) has approved the first-ever drug, iloprost, to treat severe frostbite in.
HQ Team October 20, 2023: More than half a billion people worldwide are living with diabetes, and this number is expected to rise..